Monday, September 1, 2014
Inquirer Daily News

Gemin X raises $16 million to support drug development

The Malvern biotechnology company has been working on an experimental treatment for small cell lung cancer.

Gemin X raises $16 million to support drug development

Gemin X Pharmaceuticals Inc., of Malvern, said it raised $16 million in a new round of financing.

The biotechnology company has been working on an experimental treatment for small cell lung cancer, called obatoclax.

In a statement, Gemin X chief financial officer Michael Dixon said the money would be used to support an ongoing Phase 2b clinical trial of obatoclax.

The company said current investors Caxton Advantage Life Sciences Fund L.P. and Sanderling Venture Partners co-led the financing.

Since May 2001, Gemin X has raised more than $130 million in four rounds of equity and debt financings.

Geminx X has its research and development operations in Montreal, where it was founded in 1998. Its CEO is Peter Dolan, the former CEO of Bristol-Myers Squibb.

Mike Armstrong Inquirer Columnist
About this blog
Mike Armstrong blogs about Philadelphia corporations and business-related topics. Contact him at 215-854-2980. Reach Mike at marmstrong@phillynews.com.

Mike Armstrong Inquirer Columnist
Business Videos:
Also on Philly.com:
Stay Connected